<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0204870.ref023">
 <label>23</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Ding</surname>
   <given-names>W</given-names>
  </name>, 
  <name>
   <surname>LaPlant</surname>
   <given-names>BR</given-names>
  </name>, 
  <name>
   <surname>Call</surname>
   <given-names>TG</given-names>
  </name>, 
  <name>
   <surname>Parikh</surname>
   <given-names>SA</given-names>
  </name>, 
  <name>
   <surname>Leis</surname>
   <given-names>JF</given-names>
  </name>, 
  <name>
   <surname>He</surname>
   <given-names>R</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL</article-title>. 
  <source>Blood</source>. 
  <year>2017</year>;
  <volume>129</volume>(
  <issue>26</issue>):
  <fpage>3419</fpage>â€“
  <lpage>27</lpage>. 
  <pub-id pub-id-type="doi">10.1182/blood-2017-02-765685</pub-id> ; PubMed Central PMCID: PMCPMC5492091.
  <?supplied-pmid 28424162?>
  <pub-id pub-id-type="pmid">28424162</pub-id>
 </mixed-citation>
</ref>
